No Data
No Data
List of conversion stocks (part 2) [List of stocks converting with Parabolic Signals]
○ List of stocks switched to Sell market Code Stock Name Closing Price SAR Main Board <1885> Toa Construction 1143 1199 <2181> Persol HD 229238 <2201> Morinaga Confectionery 26092692 <2212> Yamazaki Baking 27032890 <2229> Calbee 28353008 <2264> Morinaga Milk 27422935 <2270> Snow Brand Milk Products 25402712 <2301> Gakujo 2130
Hioki EE's Profit Slips 2% in 2024
List of breakout stocks (Part 1) [Ichimoku Kinko Hyo - List of breakout stocks]
List of stocks surpassing the cloud in the market Code Stock Name Closing Price Leading Span A Leading Span B Main Board <1813> Futone Tetra 2180 2071 2165 <1870> Yahagi Construction 1519 1512.75 1517.5 <1879> Shin Nihon Ken 1559 1501.5 1545 <1887> Japan National Land Development 5115 509.75 506.5 <1898> Century Tokyu 1522 1518 1512.5 <1
Stocks that moved the day before part 1: Renascience, Iwai Cosmo, Hioki Electric, ETC.
Ticker Symbol <Code> Closing Price on the 27th ⇒ Change from the previous day. Mizuho Medical <4595> 1524 +932 Financial Estimates for the fiscal year ending December 2024 revised upwards. Japan Kogyo <5279> 810 +47 Operating profit for the cumulative third quarter increased by 78.1%, shifting from a significant loss in the first half to a large profit. Toho Steel <5423> 1560 +33 Performance forecast for the fiscal year ending March 2025 revised upwards. PLANT <7646> 1537 -114 Operating profit decreased by 21.5% in the first quarter. Rena Science <4889> 1.
Spot information on individual stocks (1)
Higashi 21 <9029.T> surges. The consolidated operating profit for the cumulative third quarter of this fiscal year (April to December last year) is 1.96 billion yen (16% increase compared to the same period last year). HIOKI <6866.T> rebounds after three days. The consolidated operating profit for the fiscal year ending December 2025 is projected to be 8.34 billion yen (11% increase compared to the previous term). Sakurajima <9353.T> rebounds after three days. The consolidated financial estimates for this fiscal year have been raised. ☆ The above article contains unverified information. Provided by Wealth Advisor Inc.
Iwai Koss Corp, T Horizon, Hioki Electric, etc.
Astellas Pharma <4503> 1518.5 +16.5 significantly continues to rise. A performance revision was announced at the end of last week. The full-year operating profit has been revised down from the previous estimate of 80 billion yen to 11 billion yen, due to the impairment of the age-related macular degeneration treatment drug "Eylea" accompanied by geographic atrophy, gene therapy candidates, and ultra-small implantable Medical Devices. The impairment of Eylea itself was within the expected range, but the extent of the impairment was greater than anticipated. However, the core operating profit, due to the effects of the depreciation of the yen, has been revised from the previous 300 billion yen to 370.